Second-Line Chemotherapy in Recurrent Glioblastoma - Still ControversialFranceschi E.
Department of Medical Oncology, Bellaria-Maggiore Hospital, Azienda USL of Bologna - IRCCS Institute of Neurological Sciences, Bologna, Italy
Dr. Enrico Franceschi
Department of Medical Oncology, Bellaria-Maggiore Hospital
Azienda USL of Bologna - IRCCS Institute of Neurological Sciences
Via Altura 3, 40139 Bologna, Italy
Do you have an account?
- Carvalho BF, Fernandes AC, Almeida DS, et al.: Second-line chemotherapy in recurrent glioblastoma: a 2-cohort study. Oncol Res Treat 2015;38: DOI 10.1159/000431236.
Stark-Vance V: Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma, World Federation of Neuro-Oncology Second Quadrennial Meeting. Edinburgh, Scotland, 2005, abstr 342.
- Vredenburgh JJ, Desjardins A, Herndon JE, 2nd, et al.: Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007;25:4722-4729.
- Kreisl TN, Kim L, Moore K, et al.: Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2008;27:740-745.
- Friedman HS, Prados MD, Wen PY, et al.: Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27:4733-4740.
Brandes A, Finocchiaro G, Zagonel V, et al.: Randomized phase II trial AVAREG (ML25739) with bevacizumab (BEV) or fotemustine (FTM) in recurrent GBM: final result from the randomized phase II trial. Annals of Oncology 2014;25:iv137.
- Taal W, Oosterkamp HM, Walenkamp AM, et al.: Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol 2014;15:943-953.
- Wen PY, Macdonald DR, Reardon DA, et al.: Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010;28:1963-1972.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.